Prenetics Global Ltd (PRE) Form 6-K — Nov 18, 2026
Prenetics Global (PRE) reported Q3 2026 revenue of $64.1 million, above its $63-64 million guidance and up roughly 228% year over year, with IM8 contributing $62.9 million in its seventh consecutive record quarter. September alone generated $23.7 million of IM8 revenue, an annualized run-rate of about $284 million. The bearish offset: management widened second-half Adjusted EBITDA loss guidance to $30-35 million from the $8-12 million guided in August, a deliberate choice to step up customer acquisition spending, 70% of qualifying spend financed by the $1 billion General Catalyst facility.
Key figures
- Revenue
- 64112000
- Guidance
- FY2026 total revenue $220-230M (reaffirmed); H2 2026 Adjusted EBITDA loss revised to $30-35M from $8-12M; FY2027 IM8 revenue $400M+ (reaffirmed); year-end 2026 IM8 ARR $300M+
- Total Debt
- 34678000
- Revenue Yoy
- ~228% YoY growth (~3.3x)
- Total Assets
- 172871000
- Cash Position
- 111500000
- Shares Outstanding
- 17477654
- Gross margin
- ~64%
- Im8 revenue q3
- $62.9M (+~266% YoY)
- Cvf net fundings q3
- $31.6M
- Active subscriptions
- ~160,000
- September im8 revenue
- $23.7M
- Contribution profit q3
- $30.6M (48% margin)
- Adjusted ebitda loss q3
- -$12.7M (20% of revenue vs 39% in Q2)
- Customer acquisition cost
- ~$285 (from ~$301 in Q2)
- Adjusted free cash flow q3
- +$4.1M
- Annualized revenue run rate
- ~$284M
- General catalyst commitment
- $1 billion
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.